270 related articles for article (PubMed ID: 20824907)
41. Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
Cavo M
Leukemia; 2006 Aug; 20(8):1341-52. PubMed ID: 16810203
[TBL] [Abstract][Full Text] [Related]
42. Bortezomib in multiple myeloma.
Meisler AI
N Engl J Med; 2003 Sep; 349(13):1287-8; author reply 1287-8. PubMed ID: 14510013
[No Abstract] [Full Text] [Related]
43. NICE guidance on pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib.
Burke MJ; George E; Adler AI
Lancet Oncol; 2015 May; 16(5):492-3. PubMed ID: 25818587
[No Abstract] [Full Text] [Related]
44. Management of older patients with multiple myeloma.
Gay F; Palumbo A
Blood Rev; 2011 Mar; 25(2):65-73. PubMed ID: 21295387
[TBL] [Abstract][Full Text] [Related]
45. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.
Lacy MQ; Allred JB; Gertz MA; Hayman SR; Short KD; Buadi F; Dispenzieri A; Kumar S; Greipp PR; Lust JA; Russell SJ; Dingli D; Zeldenrust S; Fonseca R; Bergsagel PL; Roy V; Stewart AK; Laumann K; Mandrekar SJ; Reeder C; Rajkumar SV; Mikhael JR
Blood; 2011 Sep; 118(11):2970-5. PubMed ID: 21690557
[TBL] [Abstract][Full Text] [Related]
46. Hematology: Bortezomib in newly diagnosed multiple myeloma.
Berenson JR
Nat Rev Clin Oncol; 2009 May; 6(5):255-6. PubMed ID: 19390550
[TBL] [Abstract][Full Text] [Related]
47. Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations.
Taverna C; Bargetzi M; Betticher D; Gmür J; Gregor M; Heim D; Hess U; Ketterer N; Lerch E; Matthes T; Mey U; Pabst T; Renner C
Swiss Med Wkly; 2010; 140():w13054. PubMed ID: 20458652
[TBL] [Abstract][Full Text] [Related]
48. Chemotherapeutic agents increase the risk for pulmonary function test abnormalities in patients with multiple myeloma.
Bruce JT; Tran JM; Phillips G; Elder P; Mastronarde JG; Devine SM; Hofmeister CC; Wood KL
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):325-9. PubMed ID: 22986117
[TBL] [Abstract][Full Text] [Related]
49. Latest advances and current challenges in the treatment of multiple myeloma.
Mahindra A; Laubach J; Raje N; Munshi N; Richardson PG; Anderson K
Nat Rev Clin Oncol; 2012 Feb; 9(3):135-43. PubMed ID: 22349016
[TBL] [Abstract][Full Text] [Related]
50. Genomic stratification of multiple myeloma treated with novel agents.
Jiang A; Reece D; Chang H
Leuk Lymphoma; 2012 Feb; 53(2):202-7. PubMed ID: 21823830
[TBL] [Abstract][Full Text] [Related]
51. A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography.
Takasu M; Tani C; Kaichi Y; Sakoda Y; Kiguchi M; Date S; Kuroda Y; Sakai A; Awai K
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):485-92. PubMed ID: 25190250
[TBL] [Abstract][Full Text] [Related]
52. Evolving role of novel agents for maintenance therapy in myeloma.
Magarotto V; Palumbo A
Cancer J; 2009; 15(6):494-501. PubMed ID: 20010169
[TBL] [Abstract][Full Text] [Related]
53. [Recent progress in diagnosis of and therapy for multiple myeloma].
Okamoto S
Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1922-31. PubMed ID: 17037337
[No Abstract] [Full Text] [Related]
54. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.
Chanan-Khan AA; San Miguel JF; Jagannath S; Ludwig H; Dimopoulos MA
Clin Cancer Res; 2012 Apr; 18(8):2145-63. PubMed ID: 22328563
[TBL] [Abstract][Full Text] [Related]
55. Rapid improvement in renal function in patients with multiple myeloma and renal failure treated with bortezomib.
Qayum A; Aleem A; Al Diab AR; Niaz F; Al Momen AK
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):63-8. PubMed ID: 20061695
[TBL] [Abstract][Full Text] [Related]
56. Proteasome inhibition therapy: assessing the clinical implications in hematologic diseases.
ONS News; 2004; 19(9 Suppl):71-2. PubMed ID: 15478596
[TBL] [Abstract][Full Text] [Related]
57. Bortezomib for multiple myeloma.
Popat R; Joel S; Oakervee H; Cavenagh J
Expert Opin Pharmacother; 2006 Jul; 7(10):1337-46. PubMed ID: 16805719
[TBL] [Abstract][Full Text] [Related]
58. A third-generation IMiD for MM.
Cavo M
Blood; 2011 Sep; 118(11):2931-2. PubMed ID: 21921051
[No Abstract] [Full Text] [Related]
59. Clinical management of myeloma--state of the art.
Harousseau JL
Cancer Treat Rev; 2010 May; 36 Suppl 2():S1-2. PubMed ID: 20472182
[TBL] [Abstract][Full Text] [Related]
60. No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib.
Politou M; Karadimitris A; Terpos E; Kotsianidis I; Apperley JF; Rahemtulla A
Leuk Res; 2006 Feb; 30(2):240-1. PubMed ID: 16081156
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
